Rubicon Genomics Inc. extended its clinical supply agreement with Agendia for use of its TransPLEX whole genome RNA amplification technology.
Agendia uses the TransPLEX C-WTA kits for the analysis of patient samples for its MammaPrint 70-Gene breast cancer recurrence assay, which recently received 510(k) clearance from FDA. This new three-year agreement follows an earlier contract between the two companies.
Financial details of the agreement were not disclosed. TransPLEX C-WTA kits are manufactured under cGMP and are available for clinical use.
